Transcript:
In pharmaceutical research and development, R&D, companies utilize biosimulation and PBPK modeling technologies to identify and develop new therapeutic agents. Biosimulation technology holds immense potential for expediting FDA approvals while predicting toxicities and drug to drug interactions. Within the field of oncology, kinase inhibitor drug have shown efficacy in targeting complex diseases with over fifty FDA approved small molecule KIs targeting more than twenty types of protein kinases implicated in cancer pathogenesis.
But why are KI drugs prime candidates for PBPK modeling?
KI drugs are ideal subjects for PBPK modeling, due to their complex pharmacokinetic characteristics such as nonlinear absorption, extensive metabolism, and active transport cross biological membranes.
The combination of biosimulation and PBPK modeling holds vast potential in expediting FDA approvals of KI drugs while predicting toxicities and DDIs in silico modeling, unlocking new possibilities in drug discovery and health care. To learn more about the pivotal role that the Simcyp Simulator has played in advancing kinase inhibitors and informing clinical pharmacology decision making, visit certara dot com. And explore our latest scientific brief.